Business Wire

PAYRETAILERS

11.5.2023 15:28:33 CEST | Business Wire | Press release

Share
PayRetailers Appoints Jonathan Wilson as Chief Risk Officer

PayRetailers, LATAM’s leading all-in-one payment technology provider, has appointed Jonathan Wilson as its new Chief Risk Officer (CRO). With this appointment, PayRetailers is taking another step forward in its mission to provide secure and reliable payment solutions to its growing customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005026/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jonathan Wilson, Chief Risk Officer at PayRetailers (Photo: PayRetailers)

As CRO, Wilson will be responsible for overseeing the company’s operational and credit risk as well as risk management strategy.

A risk management heavyweight

Jonathan Wilson boasts industry leading experience reducing risk exposure and elevating security profiles for cutting-edge global payments organizations. He served as Head of Risk for the Digital Wallets division at PaySafe for over a decade, where he led on risk management and data analytics, and implemented a control framework and anti-fraud and anti-money laundering practices.

Prior to joining PayRetailers, Wilson was Chief Risk and Compliance Officer (CRCO) at AU10TIX, responsible for providing identity verification and fraud detection services to numerous services and fintech businesses. As CRCO, he led his team through the development of a new enterprise risk management framework and risk management processes.

Wilson’s professional experience also encompasses assessing risk management effectiveness, identifying operational and financial risks, and implementing innovative internal controls, policies and processes to reduce risk and monitoring results of implemented improvement. He has managed relationships with domestic and international regulatory oversight organizations, and built awareness by aligning key stakeholders enterprise-wide.

The appointment comes at a time of strong growth for PayRetailers, as it continues to expand to new markets in Latin America and bolsters its senior leadership team.

Jonathan Wilson, Chief Risk Officer at PayRetailers, commented: “PayRetailers is playing a critical role as it delivers financial opportunity to underbanked markets across LATAM. It’s an exciting opportunity to bring my risk and compliance experience to a company with a clear vision and powerful purpose. PayRetailers is driving impressive growth that demands impeccable risk and compliance - as the company provides high quality, secure and easy to use payment platforms to retailers across the region.”

Juan Pablo Jutgla, CEO & Founder of PayRetailers, commented: “Jonathan strengthens the PayRetailers offering as he brings world-class expertise in developing and implementing effective risk management processes. As we continue to expand into new markets, grow into new verticals, and deliver new products, risk management becomes and increasing priority. Wilson will play an invaluable role in elevating our control mechanisms to ensure we continue to provide safe and reliable payment solutions to our customers.”

For more information about PayRetailers, please visit the company's website at https://payretailers.com

About PayRetailers

Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offer global merchants more than payment methods without the need of a local entity.

PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions.

PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay, Peru and Uruguay.

Website: https://www.payretailers.com

LinkedIn: https://www.linkedin.com/company/pay-retailers/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005026/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye